8 months ago
India Bans High-Dose Nimesulide Oral Medications
The Indian government has banned the sale and distribution of high-dose Nimesulide oral medications, which are pain and fever drugs.
This ban is because these high doses might be harmful to the liver and have other bad effects.
The ban only applies to doses above 100 mg, and lower doses are still allowed.
The government says there are safer alternatives available.
Big drug companies might not be affected much, but smaller ones that sell a lot of Nimesulide might have some problems.
India has also been investing a lot of money to make more of the important ingredients needed to make medicines, so they don't have to rely on other countries as much.
India has banned the manufacture, sale, and distribution of oral Nimesulide formulations above 100 mg in immediate-release dosage form.
The ban is based on potential liver toxicity and other adverse effects, with safer alternatives available.
Only high-dose products for human use are banned, while lower-dose formulations remain available.
Pharmaceutical companies must halt production and recall impacted batches, with limited financial impact expected on large drugmakers.
India has invested significantly in domestic active pharmaceutical ingredient manufacturing to reduce supply disruption risks.
- Who
- Indian Health Ministry and Drugs Technical Advisory Board
- What
- Ban on high-dose Nimesulide oral medications
- Where
- India
- When
- Immediate effect
- Why
- Potential liver toxicity and other adverse effects, with safer alternatives available
Health and Safety Advocates
Pharmaceutical Industry
Ban Justification
Health and Safety Advocates
The ban is necessary to protect public health due to potential liver toxicity and other adverse effects of high-dose Nimesulide.
Pharmaceutical Industry
The ban may disproportionately affect smaller pharmaceutical companies that rely heavily on Nimesulide sales, potentially leading to revenue pressure.
Key facts
- Drug
- Nimesulide (oral formulations above 100 mg)
- Action
- Ban on manufacture, sale, and distribution
- Effective Date
- Immediate
- Authority
- Health Ministry, Drugs Technical Advisory Board
- Reason
- Potential liver toxicity and other adverse effects
- Impact
- Limited financial impact on large drugmakers, potential revenue pressure on smaller firms
- Alternatives
- Lower-dose formulations and other therapeutic options available
- PLI Scheme Investment
- Rs 4,763.34 crore (till September 2025)
Timeline
India uncovers faulty drugs, sparks safety probe.
Scrutiny intensifies, Nimesulide gets box warning.
Previous warning triggers high-dose ban.
India bans high-dose Nimesulide, citing liver risks.
Quotes
Notification from the Ministry of Health and Family Welfare
Official notification from the Ministry of Health and Family Welfare
“In exercise of the powers conferred by section 26A of the Drugs and Cosmetics Act, 1940, and after consultation with the Drugs Technical Advisory Board (DTAB), the central government hereby prohibits the manufacture, sale and distribution of all oral formulations of the following drug (Nimesulide), with immediate effect.”
financialexpress.com
Anay Shukla
Founding partner at Arogya Legal
“Even though the government has the right to take such decisions in the public interest, the industry is going to suffer from the immediate ban. The negative effects of the drugs have not been discovered recently, and the government is mulling potential ban since last year. It would have been fair if the government had given a window to the manufacturers and distributors to exhaust their current inventory, considering that it’s a top-selling medicine in the country.”
financialexpress.com
Sources
Govt bans manufacture, sale of oral formulations containing nimesulide above 100 mg-Here's why
Health Ministry bans nimesulide oral tablets, syrups over 100 mg, removes cough syrups from OTC sales
Health Ministry bans oral formulations of painkiller nimesulide above 100 mg, cites safety risks
Health Ministry Bans Nimesulide Oral Doses Above 100 Mg Over Safety Concerns
India bans oral Nimesulide over 100 mg
Centre Bans High-Dose Nimesulide Oral Formulations
Nimesulide ban: Govt bars sale of oral painkiller doses above 100 mg
Health Ministry Bans Nimesulide Oral Doses Above 100 Mg Over Safety Concerns
Nimesulide oral formulations of over 100 mg banned by the central government due to health risks
Centre bans oral formulations of popular painkiller Nimesulide over 100 mg
Govt bans popular painkiller drug Nimesulide; experts call the immediate ban unfair
Related news
India Tightens Cough Medicine Rules for Children Under Four
India Extends Restrictions on Two-Ingredient Medicines for Under-Four Children
Haryana Bans High-Dose Nimesulide Oral Formulations
India to Restrict Unlicensed Cough Syrup Sales in Villages
